• Part of
    Ubiquity Network logo
    Join Mailing List Publish with us

    Read Chapter
  • No readable formats available
  • Why Open Drug Discovery Needs Four Simple Rules for Licensing Data and Models

    Antony J Williams John Wilbanks Sean Ekins

    Chapter from the book: Moore, S. 2014. Issues in Open Research Data.


    First paragraph: Public online databases supporting life sciences research have become valuable resources for researchers depending on data for use in cheminformatics, bioinformatics, systems biology, translational medicine, and drug repositioning efforts, to name just a few of the potential end user groups (Williams et al. 2009). Worldwide funding agencies (governments and not-for-profits) have invested in public domain chemistry platforms. In the United States these include PubChem, ChemIDPlus, and the Environmental Protection Agency’s ACToR, while the United Kingdom has funded ChEMBL and ChemSpider, among others, and new databases continue to appear annually (National Center for Biotechnology Information, n.d.; US National Library of Medicine, n.d.; Judson et al. 2008; EMBL-EBI, n.d.; Pence & Williams 2010; Galperin & Cochrane 2011).

    Chapter Metrics:

    How to cite this chapter
    Williams, A et al. 2014. Why Open Drug Discovery Needs Four Simple Rules for Licensing Data and Models. In: Moore, S (ed.), Issues in Open Research Data. London: Ubiquity Press. DOI: https://doi.org/10.5334/ban.e

    This is an Open Access chapter distributed under the terms of the Creative Commons Attribution 4.0 license (unless stated otherwise), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. Copyright is retained by the author(s).

    Peer Review Information

    This book has been peer reviewed. See our Peer Review Policies for more information.

    Additional Information

    Published on Dec. 19, 2014


    comments powered by Disqus